AU2019344868B2 - TLR8 agonist - Google Patents

TLR8 agonist Download PDF

Info

Publication number
AU2019344868B2
AU2019344868B2 AU2019344868A AU2019344868A AU2019344868B2 AU 2019344868 B2 AU2019344868 B2 AU 2019344868B2 AU 2019344868 A AU2019344868 A AU 2019344868A AU 2019344868 A AU2019344868 A AU 2019344868A AU 2019344868 B2 AU2019344868 B2 AU 2019344868B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019344868A
Other languages
English (en)
Other versions
AU2019344868A1 (en
Inventor
Zhe CAI
Shuhui Chen
Charles Z. Ding
Fei Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AU2019344868A1 publication Critical patent/AU2019344868A1/en
Application granted granted Critical
Publication of AU2019344868B2 publication Critical patent/AU2019344868B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019344868A 2018-09-19 2019-09-19 TLR8 agonist Active AU2019344868B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811094969.4 2018-09-19
CN201811094969 2018-09-19
PCT/CN2019/106687 WO2020057604A1 (zh) 2018-09-19 2019-09-19 Tlr8激动剂

Publications (2)

Publication Number Publication Date
AU2019344868A1 AU2019344868A1 (en) 2021-04-15
AU2019344868B2 true AU2019344868B2 (en) 2024-06-27

Family

ID=69888288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019344868A Active AU2019344868B2 (en) 2018-09-19 2019-09-19 TLR8 agonist

Country Status (11)

Country Link
US (1) US12054482B2 (https=)
EP (1) EP3854794B1 (https=)
JP (1) JP7498702B2 (https=)
KR (1) KR102856089B1 (https=)
CN (2) CN112805283B (https=)
AU (1) AU2019344868B2 (https=)
CA (1) CA3112953A1 (https=)
ES (1) ES2999323T3 (https=)
PH (1) PH12021550601A1 (https=)
SG (1) SG11202102641RA (https=)
WO (1) WO2020057604A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist
EP4122931B1 (en) * 2020-03-18 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline form of tlr8 agonist
CN116472047B (zh) * 2021-11-05 2025-06-17 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist

Also Published As

Publication number Publication date
JP7498702B2 (ja) 2024-06-12
EP3854794A1 (en) 2021-07-28
JP2022501350A (ja) 2022-01-06
AU2019344868A1 (en) 2021-04-15
ES2999323T3 (en) 2025-02-25
US12054482B2 (en) 2024-08-06
CN112805283A (zh) 2021-05-14
WO2020057604A1 (zh) 2020-03-26
SG11202102641RA (en) 2021-04-29
PH12021550601A1 (en) 2021-11-29
KR102856089B1 (ko) 2025-09-04
CN115650979A (zh) 2023-01-31
KR20210060567A (ko) 2021-05-26
CA3112953A1 (en) 2020-03-26
US20210371414A1 (en) 2021-12-02
EP3854794A4 (en) 2022-06-15
CN112805283B (zh) 2022-09-20
EP3854794B1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
EP3416946B1 (en) Tetracyclic pyridone compounds as antivirals
EP2485737B1 (en) Novel trpa1 antagonists
AU2019344868B2 (en) TLR8 agonist
JP2020530452A (ja) 大員環免疫調節剤
CN114206338B (zh) 作为pd-l1抑制剂的二氢化茚类
EP1154988B1 (en) Mevinolin derivatives
AU2019361697B2 (en) TLR8 agonist
US11466024B2 (en) Bicylic compound acting as an inhibitor
CN109096219B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
US20250282747A1 (en) Methods and compounds useful in the synthesis of an aak1 inhibitor
CN108137608A (zh) Janus激酶1选择性抑制剂及其药物用途
RU2800877C2 (ru) Агонист tlr8
US20170007610A1 (en) Novel heterobicyclic compounds as kappa opioid agonists
HK40048022B (en) Tlr8 agonist
EP4122931B1 (en) Crystalline form of tlr8 agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)